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Abstract: (Poly)phenol-derived metabolites are small molecules resulting from (poly)phenol metabo-
lization after ingestion that can be found in circulation. In the last decade, studies on the impact of
(poly)phenol properties in health and cellular metabolism accumulated evidence that (poly)phenols
are beneficial against human diseases. Diabetic retinopathy (DR) is characterized by inflammation
and neovascularization and targeting these is of therapeutic interest. We aimed to study the effect of
pyrogallol-O-sulfate (Pyr-s) metabolite in the expression of proteins involved in retinal glial activa-
tion, neovascularization, and glucose transport. The expression of PEDF, VEGF, and GLUT-1 were
analyzed upon pyrogallol-O-sulfate treatment in RPE cells under high glucose and hypoxia. To test
its effect on a diabetic mouse model, Ins2Akita mice were subjected to a single intraocular injection of
the metabolite and the expression of PEDF, VEGF, GLUT-1, Iba1, or GFAP measured in the neural
retina and/or retinal pigment epithelium (RPE), two weeks after treatment. We observed a significant
decrease in the expression of pro-angiogenic VEGF in RPE cells. Moreover, pyrogallol-O-sulfate
significantly decreased the expression of microglial marker Iba1 in the diabetic retina at different
stages of disease progression. These results highlight the potential pyrogallol-O-sulfate metabolite as
a preventive approach towards DR progression, targeting molecules involved in both inflammation
and neovascularization.
Keywords: diabetic retinopathy; inflammation; neovascularization; retinal pigment epithelium; hy-
perglycemia
1. Introduction
In the last decades, studies on the impact of (poly)phenols in health and cellular
metabolism have accumulated evidence that (poly)phenols are beneficial against human
diseases. Particularly in the context of diabetic retinopathy (DR), the beneficial effects of
resveratrol (RES) on neovascularization and oxidative stress were observed more than
a decade ago [1,2].
(Poly)phenols are members of a large family of compounds, chemically characterized
by the presence of one or more hydroxyl groups attached to an aromatic ring. Polyphenols’
metabolites, with potential health-promoting effects, have been studied in experimental
cell cultures and animal models, as well as human clinical studies [3–7]. However, when
trying to correlate the beneficial health effects described for dietary (poly)phenols and their
bioavailability in humans, it is often observed that some of these compounds are poorly
absorbed and may undergo several metabolic modification steps, including metabolism
in the colon by the resident microbiota. Therefore, it is crucial to look for the metabolite’s
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bioactivity instead of its parent dietary compounds for relevant insights for its potential
preventive or therapeutic effect. Previous studies have shown the presence in human
plasma of sulfated metabolites of pyrogallol in volunteers after ingestion of a fruit purée [6],
which was found to reach concentrations up to 20 µM. Among the metabolites found in
this study, concentrations of pyrogallol-O-sulfate (Pyr-s) were found to be significantly
higher when compared to the baseline [6], raising some interest in their therapeutic value.
There are several studies on the anti-diabetic effects of dietary (poly)phenols. These
compounds influence glycemia through mechanisms such as the inhibition of glucose
absorption in the gut or in peripheral tissues [8]. However, studies specifically related to
the effect of (poly)phenols or their metabolites on retinal diseases are scarce. Recently, the
beneficial effect of different carotenoids and (poly)phenols in the prevention and treatment
of age-related ocular disorders was reviewed, highlighting the role of these plant deriva-
tives in reducing oxidative stress and inflammation [9]. Ola et al. reviewed evidence on the
potential metabolic sources and pathways related to the increase of oxidative stress in DR
and the role of dietary flavonoids, particularly flavanones, flavanols, isoflavones, flavones,
and anthocyanins, in the modulation of redox homeostasis in the diabetic retina [10].
Specifically, epigalloccatechin-3-gallate, the main (poly)phenol component of green tea
(leaves of Camellia sinensis), was identified as an inhibitor of ocular angiogenesis with influ-
ence in ocular vascular permeability after orally administrated in male BALB/c mice [9].
Therefore, oral treatment with nutraceuticals at early stages of DR may represent a reason-
able alternative to act upstream of the disease, preventing its progression. The effect of
pyrogallol-O-sulfate was particularly investigated towards neuroinflammation [3] and car-
diomyocyte stress [5]. Moreover this metabolite have the ability to cross of the blood–brain
barrier and present neuroprotective properties [3]. As far as we know, no studies were
published highlighting the effect of pyrogallol-O-sulfate metabolite in ocular structures.
Vascular endothelial growth factor (VEGF), particularly VEGF-A, is a protein from
a large family of angiogenic proteins, that is secreted by different cells in retina, mostly
by the basolateral side of RPE. The main functions of these proteins are the regulation of
angiogenesis and vascular permeability, with several studies correlating the imbalance in
its expression and of its receptors with the severity of DR and age-related macular degener-
ation (AMD) [11,12]. On the other side, there is one of the most relevant molecules of the
RPE secretome, pigment epithelium-derived factor (PEDF), an apically secreted protein
from the serine protease inhibitor (serpin) super family. In 1999, PEDF was identified as
an anti-angiogenic factor which prompted it immediately being considered as a potential
therapeutic target for diabetes mellitus [13]. Shortly after its discovery, low levels of PEDF
were correlated with retinitis pigmentosa and Lebers’ congenital amaurosis [13], and also
found to be decreased in the retinas from patients with proliferative DR and retinopathy
of prematurity [14,15]. The transport of glucose in the human retina was investigated
at various ages and found to be exclusively mediated by one of the 12 isoforms of the
sodium-independent glucose transporter (GLUT), GLUT-1, expressed in the endothelia of
the retinal capillaries of the retina and RPE basal membrane, both part of the blood-retinal
barrier (BRB) [16]. Based on a gradient concentration, GLUT-1 adapts the bidirectional
transport of glucose to different situations, such as hypoxia, growth factors, and glucose
levels itself [17].
In this work, we aimed to study the effect of pyrogallol-O-sulfate in RPE cells and
in the diabetic retina, particularly in the expression of molecules involved in DR-related
neovascularization and retinal glial activation with the goal of assessing its potential in
ameliorating diabetic retinopathy.
2. Results
2.1. Metabolic Activity of RPE Cells Is Not Affected by Treatment with Pyrogallol-O-Sulfate
As a first approach, to determine the effect of Pyr-s on retinal cells, we investigated the
metabolic activity of RPE cells upon treatment with this metabolite. Although no studies
were conducted, so far, aiming to evaluate the ability of these metabolites to cross the BRB,
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the mean concentration of metabolites found in the plasma of human volunteers 4 h after
the ingestion of the fruit purée—6.5 µM, [6]- was chosen to perform the assays. To model
the conditions found in the DR retina, we established an in vitro model of hypoxia and
hyperglycemia, as described in the Materials and Methods (Section 4.2). To measure the
metabolic activity in RPE cells exposed to Pyr-s for 24 h upon exposure to hypoxia for 16 h,
an MTT assay was performed.
As observed in Figure 1, the RPE cells under hypoxia for 16 h were not metabolically
affected by the treatment with Pyr-s, with percentages above 80% in all experimental
conditions, which is considered the acceptable threshold for most cells in culture [11].
No differences were observed regardless the levels of glucose or treatment.
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(HG, 25 mM glucose) with chemically induced hypoxia for 16 h (DFO 100 µM), assessed by the MTT 
assay. n = 4. Values are expressed as percentage of control (NG, normal glucose under normoxia). 
Mannitol (M) was used as the osmolarity control. 
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sion of several markers of inflammation [3]. Here, we were interested in applying the same 
hypothesis regarding hypoxia, which has a well-known role in trigger neovascularization. 
Moreover, the imbalance between pro-and anti-angiogenic proteins is also considered as 
one of the main contributors to disease progression [12], also promoting neovasculariza-
tion. However, the new blood vessels are usually weak, fragile, and leaky, which allows 
proteins, fluids, and debris to enter the retina [13,14]. 
Figure 1. Effect of pyrogallol-O-sulfate (6.5 µM, 24 h) on the metabolic activity of RPE cells under
high glucose and hypoxia. Viability of RPE cells under normal (NG, 5.5 mM glucose) or high glucose
(HG, 25 mM glucose) with chemically induced hypoxia for 16 h (DFO 100 µM), assessed by the MTT
assay. n = 4. Values are expressed as percentage of control (NG, normal glucose under normoxia).
Mannitol (M) was used as the osmolarity control.
2.2. Pre-Treatment of RPE Cells with Pyrogallol-O-Sulfate before Hypoxia Has No Significant
Effect on the Expression of Neovascularization-Related Proteins
(Poly)phenol- eri et lit a bee studied for their potential to prevent
neuroinfla atio an recent studies sho that pre-incubation of microglial cells with
pyrogal ol-O-sulfate before lipopolysaccharide (LPS) insult is able to decrease the ex res-
sion of several arkers of inflammation [3]. ere, we ere interested in applying the same
hypothesis regarding hypoxia, which has a el -kno n role in tri er l rization.
oreover, the imbalance betwe n pro-and anti-angiogenic proteins is also considered as
one of the main contributors to disease progression [12], also prom ting neovasculariz tion.
H wever, the new blood vessels are usu lly weak, fragile, and leaky, which allows proteins,
fluids, and debris to ente the r tina [13,14].
Our hypothesis is that in RPE cells under high glucose, treatment with Pyr-s before
inducing hypoxia prevents the dysregulation of anti-angiogenic PEDF and pro-angiogenic
VEGF. Additionally, the expression of the glucose transporter GLUT-1, known to be in-
creased in cells under high glucose and hypoxia [15], is also expected to be downregulated
by treatment with Pyr-s before the hypoxic insult.
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Figure 2 shows the relative expression of PEDF, VEGF, and GLUT-1 in cells cultured
in normal glucose (NG) and exposed to high glucose (HG) for 24 h before treatment under
normoxia and hypoxia, with and without Pyr-s treatment. RPE cells were exposed to Pyr-s
up to 8 h before hypoxia, with a 2 h interval. Cells in normal glucose and normoxia were
considered the control condition, as representative of the physiological situation.
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The expression of PEDF (Figure 2A), VEGF (Figure 2B), or GLUT-1 (Figure 2C) is not
significantly altered by pre-treatment with Pyr-s before the hypoxic insult, in any of the
timepoints evaluated, compared to the physiologic condition (cells under nomoglucose
(NG) and normoxia). However, a tendency for pre-treatment of RPE cells with Pyr-s
for 2 (p = 0.0885) or 6 h (p = 0.1148) before hypoxia to decrease the expression of PEDF
is observed (Figure 2A), when treated cells under hypoxia are compared to cells under
normoglucose and hypoxia (determined by Two-way ANOVA with Dunnett’s multiple
comparisons test), as we have previously defined a trend to be considered when the p value
is below 0.25. Moreover, the expression of the proteins of interest in non-treated RPE cells
are not altered by hypoxia or high glucose.
2.3. Treatment of RPE Cells with Pyrogallol-O-Sulfate after Hypoxia Does Not Compromise the
Expression of PEDF, VEGF, Or GLUT1
Most DR cases are diagnosed at later stages, where ischemia is already established
and is the main cause of neovascularization promoted by the increase in the levels of VEGF
in the retina. Here we address the hypothesis that RPE cells benefit from treatment with
pyrogallol-O-sulfate after being exposed to high glucose and chemically induced hypoxia,
decreasing the expression of pro-angiogenic VEGF and glucose transporter GLUT-1 and
increasing the expression of anti-angiogenic PEDF, therefore restoring the balance in the
expression of these proteins. The expression of pro- (VEGF) and anti-angiogenic (PEDF)
factors and GLUT-1 was evaluated in RPE cells treated with pyrogallol-O-sulfate for 8 h
after induction of hypoxia.
Figure 3 shows the relative expression of PEDF, VEGF, and GLUT-1 in cells without
(NT) or with Pyr-s treatment. Values measured in cells under hypoxia were normalized
for the respective control in normoxia (Supplementary Figure S5). Cells in normal glu-
cose without treatment were considered the control experimental condition for statistical
analysis purposes, as representative of the physiological situation.
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 5 of 23 
 
 
Figure 2. Effect of pre-treatment of pyrogallol-O-sulfate on RPE cells for 8 h in normal (5.5 mM 
glucose) and high (25 mM glucose) glucose before chemically induced hypoxia for 16 h (DFO, 100 
µM). RPE cells were exposed to a single dose of Pyr-s, as pre-treatment, up to 8 h before hypoxia. 
The metabolite was removed from the cell culture after the incubation period. Western blots are a 
representative image used for the densiometric analysis of (A) PEDF, (B) VEGF, and (C) GLUT-1 
protein levels in RPE cells after Pyr-s pre-treatment, normalized by the intensity of β-Actin. n = 5. 
The expression of PEDF (Figure 2A), VEGF (Figure 2B), or GLUT-1 (Figure 2C) is not 
significantly altered by pre-treatment with Pyr-s before the hypoxic insult, in any of the 
timepoints evaluated, compared to the physiologic condition (cells under nomoglucose 
(NG) and normoxia). However, a tendency for pre-treatment of RPE cells with Pyr-s for 2 
(p = 0.0885) or 6 h (p = 0.1148) before hypoxia to decrease the expression of PEDF is ob-
served (Figure 2A), when treated cells under hypoxia are compared to cells under 
normoglucose and hypoxia (determined by Two-way ANOVA with Dunnett’s multiple 
comparisons test), as we have previously defined a trend to be considered when the p 
value is below 0.25. Moreover, the expression of the proteins of interest in non-treated 
RPE cells are not altered by hypoxia or high glucose. 
2.3. Treatment of RPE Cells with Pyrogallol-O-Sulfate after Hypoxia Does Not Compromise the 
Expression of PEDF, VEGF, Or GLUT1 
Most DR cases are diagnosed at later stages, where ischemia is already established 
and is the main cause of neovascularization promoted by the increase in the levels of 
VEGF in the retina. Here we address the hypothesis that RPE cells benefit from treatment 
with pyrogallol-O-sulfate after being exposed to high glucose and chemically induced hy-
po ia, decreasing the expression of pro-angiogenic VEGF and glucose transporter GLUT-
1 and increasing the expression of anti-angiogenic PEDF, therefore restoring the balance 
in the expression of these proteins. The expression of pro- (VEGF) and anti-angiogenic 
(PEDF) factors and GLUT-1 was evaluated in RPE cells treated with pyrogallol-O-sulfate 
for 8 h after induction of hypoxia. 
Figure 3 shows the relative expression of PEDF, VEGF, and GLUT-1 in cells without 
(NT) or with Pyr-s treatment. Values measured in cells under hypoxia were normalized 
for the respective control in normoxia (Supplementary Figure S5). Cells i  normal glucose 
with ut treatment were considered the control experimental condition for statistical anal-
ysis purposes, as representative of the physiological situation.  
Treatment of RPE c lls und r high glucose (HG) with Pyr-s for 8 h after hypoxia does 
not alte  the expre sion of PEDF (Figure 3A), VEGF (Fig re 3B), or GLUT-1 (Figure 3C), 
compared to non-treated cells under normoglucose. When comparing RPE cells treated 
with Pyr-s with non-treated (NT) cells und r high glucose (HG), there is als  no d ffer-
ences in the expr sion of PEDF, VEGF, or GLUT-1. 
 
Figure 3. Effect of treatment of RPE cells under normal (NG, 5.5 mM glucose) or high glucose (HG, 25 mM glucose) with
pyrogallol-O-sulfate for 8 h after chemically induced hypoxia for 16 h (DFO, 100 µM). RPE cells were exposed to a single
dose of Pyr-s after induction of hypoxia. Cells were exposed to the metabolite for 8 h. Western blots are a representative
image used for the densiometric analysis of (A) PEDF, (B) VEGF, and (C) GLUT-1 protein levels in RPE cells after Pyr-s
treatment, normalized by the intensity of β-Actin. n = 5. Two-way ANOVA with Sidak’s multiple comparisons test. NT,
non-treated; Pyr-s, pyrogallol-O-sulfate.
Treatment of RPE cells under high glucose (HG) with Pyr-s for 8 h after hypoxia does
not alter the expression of PEDF (Figure 3A), VEGF (Figure 3B), or GLUT-1 (Figure 3C),
compared to non-treated cells under normoglucose. When comparing RPE cells treated
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with Pyr-s with non-treated (NT) cells under high glucose (HG), there is also no differences
in the expression of PEDF, VEGF, or GLUT-1.
2.4. Treatment of RPE Cells with Pyrogallol-O-Sulfate for 24 H Decreases the Expression of
Pro-Angiogenic VEGF
In previous experimental approaches, we analyzed the effect of Pyr-s as protector of
the deleterious effects induced by hypoxia on RPE cells and its potential role in reverting
those effects after hypoxia is already established. However, we were also interested in the
hypothesis of a beneficial effect of more prolonged exposure of RPE cells to Pyr-s. To test
this hypothesis, Pyr-s was added to the cell medium 8 h before induction of hypoxia and
maintained up to 24 h. The expression levels of PEDF, VEGF, and GLUT-1 were measured
in whole cell lysates by Western blot.
Figure 4 shows the relative expression of PEDF, VEGF, and GLUT-1 in cells in normal
glucose (NG) and high glucose (HG) under normoxia and hypoxia with and without
treatment with Pyr-s up to 24 h. Cells in normal glucose under normoxia were considered
the control experimental condition.
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When cells were exposed to Pyr-s before induction of hypoxia, with Pyr-s remaining
in the cell medium for 24 h, the expression of VEGF significantly decreased, compared to
cells in normal glucose cells and normoxia (Figure 4B). Moreover, cells in high glucose
and hypoxia showed an increase in VEGF, as described before, which was prevented by
treatment with Pyr-s for 24 h (Figure 4B). The expression of either PEDF or GLUT-1 was
not altered by treatment with Pyr-s in these conditions (Figure 4A,C).
Taking together the results from the three experimental approaches, described and
schematized in detail in Materials and Methods (Section 4.3), regarding the effect of Pyr-s
on the expression of PEDF, VEGF, and GLUT-1 in RPE cells, we can observe that the time
of exposure caused different outcomes.
When cells were pre-treated with Pyr-s up to 8 h before being exposed to hypoxia, a
tendency to decrease the expression of PEDF (Figure 2A) at different timepoints of treatment
was observed. When cells were exposed to Pyr-s after hypoxia was fully established, the
expression of our proteins of interest was not altered. The prolonged exposure of RPE
cells under high glucose and hypoxia to Pyr-s significantly decreased the expression of
pro-angiogenic VEGF, compared to both physiological conditions (normoglycemia and
normoxia) and non-treated cells under high glucose and hypoxia (Figure 4B).
To extend our studies to a diabetic animal model, a proof-of-concept protocol was
designed based on the least invasive strategy and best approach for a therapeutic effect
using the pyrogallol-O-sulfate.
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2.5. A Single Intraocular Injection of Pyrogallol-O-Sulfate Decreases the Expression of Microglial
Marker Iba1 in The Retina of a Diabetic Mice
Chronic inflammation has been associated with DR progression, characterized by
increased cytokine production and the activation of micro and macroglia cells [16,17].
Although RPE is not the major contributor of cytokines and other inflammatory players, in
response to the inflammatory environment, retinal microglia may become overactivated,
up-regulating pro-inflammatory factors that induce oxidative stress, neuronal degener-
ation, and neovascularization [17–20], affecting other retinal cell layers and promoting
disease progression.
We have previously characterized the expression of several markers of DR progression
in a spontaneous Type 1 Diabetes Mellitus model, the Ins2Akita, and found an increase in the
expression of microglia marker Iba1 in the neural retina of 6 month-old diabetic mice [12].
At the same time point, the expression of GFAP decreases in diabetic retina, compared to
the non-diabetic retina [12].
In this context, we analyzed the protein levels of Iba1, as a marker of microglia
activation, and GFAP, a glial intermediate filament expressed by astrocytes, in the retina
of 4-, 6-, 8-, and 9-month-old male heterozygote Ins2Akita mice two weeks after a single
intraocular injection of Pyr-s, targeting the neural retina or the RPE.
The experimental design is described and schematized in detail in the Materials and
Methods (Section 4.7.2). Briefly, diabetic and age-matched non-diabetic animals were
randomly divided into two groups, one receiving a single intraocular injection of Pyr-s
and the other receiving the vehicle solution. After two weeks, the retina and RPE of
the mice were isolated for Western blot analysis of the expression of proteins of interest.
The time-points chosen were related to early DR progression in this mice model, where
inflammation has a very important role [12,21].
Blood glucose levels and body weight were measured at the time of injection (Figure 5).
Ins2Akita mice weighed significantly less in all time points evaluated compared with control
mice (Figure 5). Additionally, Ins2Akita mice displayed significantly increased concen-
trations of blood glucose compared with non-diabetic mice at all analyzed time points
(Figure 5). These data are consistent with previous reports in the literature [21,22].
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Figure 5. Body weight and blood glucose levels of non-diabetic and diabetic mice of 4, 6, 8, and 9 months of age. Values 
are represented as mean ± SD. * p < 0.05, *** p < 0.001, **** p < 0.0001 is significantly different compared to non-diabetic 
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i re 5. Body weight and blo d glucose levels of non-diabetic and iabetic mice of 4, 6, 8, and 9 months of age. Values are
represented as mean ± SD. * p < 0.05, *** p < 0.001, **** p < 0.0001 is significa tly different compared to non-diabetic mice,
determin d by Sidak’s multiple comparisons test. n = 8 for non-diabetic nd n = 10 for diabetic.
The results for the expression of Iba1 and GFAP, normalized for levels of expression of
the contralateral non-injected eye, are plotted in Figures 6 and 7, respectively. No differences
were observed in the expression of any of the proteins evaluated upon intraocular injection
of vehicle solution, when the vehicle was compared to the contralateral non-injected eye,
with an exception for the expression of GFAP in non-diabetic retina of 6-month-old animals
(Supplementary Figures S1–S4).
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of either vehicle or Pyr-s in 4-month-old animals (Figure 6A). However, as previously ob-
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diabetic mice upon intravitreal injection of Pyr-s (Figure 7A). Moreover, as previously de-
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old mice when non-diabetic retinas were compared to diabetic retinas (Figure 7B). Treat-
ment of diabetic retinas with Pyr-s tends to increase the expression of GFAP (p = 0.2468) 
at the same time-point (Figure 7B). No differences in the expression of GFAP were ob-
served in older mice, subretinally injected, although there was a tendency of treatment 
with Pyr-s decreasing the expression of GFAP (p = 0.2490), when non-diabetic retinas of 
8-month-old mice were compared to diabetic (Figure 7C). 
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Figure 7. Expression of GFAP in Ins2Akita mice after a single intravitreal or subretinal injection of pyrogallol-O-sulfate. 
Protein expression levels and representative Western blot images for the densitometric analysis in the retina of Ins2Akita 
(diabetic) mice and age-matched non-diabetic mice, of 4 (A), 6 (B), 8 (C), and 9 (D) months old, intravitreal or subretinally 
injected with vehicle or Pyr-s. Protein levels were normalized to β-actin. Data are expressed as mean ± SD (n = 2 to 6 
mice/group) * p < 0.05 by two-way ANOVA (genotype and treatment) with Sidak’s multiple comparison test. 
In a previous study, we showed that the expression of Iba1 tends to increase in the 9-
month-old diabetic retina but is not altered in older mice [12]. Here, we analyzed the ex-
pression of Iba1 and GFAP in 8- and 9-month-old mice to understand if the administration 
of Pyr-s before an advanced stage of DR (as previously established to be at 9 months) has 
a positive effect on retinal homeostasis. Treatment of diabetic 9-month-old mice with a 
single subretinal injection tends to decrease the expression of Iba1 in the neural retina 
(Figure 6D) and has no effect in the 8-month-old mice (Figure 6C). Furthermore, the ex-
pression of GFAP was not affected by Pyr-s in 8- (Figure 7C) or 9-month-old (Figure 7D) 
animals. 
2.6. A Single Subretinal Injection of Pyrogallol-O-Sulfate Decreases the Expression of Pro-
Angiogenic VEGF in the RPE of a Diabetic Mouse Model 
We have previously documented the dysregulation of the balance between pro- and 
anti-angiogenic factors in the Ins2Akita mouse, with a significant increase in the expression 
of VEGF with a concomitant decrease in the expression of PEDF in the neural retina of 9-
month-old mice [12]. 
To further evaluate the effect of pyrogallol-O-sulfate in the expression profile of pro- 
and anti-angiogenic factors with disease progression in the Ins2Akita mouse, we evaluated 
the protein levels of PEDF (Figure 8) and VEGF (Figure 9) in neural retina and RPE cells 
of 4-, 6-, 8-, and 9-month-old mice two weeks after intraocular injection of Pyr-s, as de-
scribed in Materials and Methods (Section 4.7.2). We were also interested in evaluating 
the expression of glucose transporter, GLUT-1, as its expression was previously reported 
to be imbalanced in diabetic retinas [15] (Figure 10).  
The expression of anti-angiogenic PEDF was not altered in the neural retina of either 
non-diabetic or diabetic mice, either by intraocular injection of vehicle or Pyr-s, at any of 
the time-points evaluated (Figure 8A–D). Similarly, no differences were observed in the 
RPE, independently of the genotype (Figure 8 E–H). 
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Our results show that the expression of Iba1 was not altered by intraocular injection
of either vehicle or Pyr-s in 4-month-old animals (Figure 6A). However, as previously
observed [12], the expression of Iba1 increased in 6-month-old mice when comparing
the retinas injected with the PBS vehicle from non-diabetic and diabetic mice (Figure 6B).
The treatment of diabetic retinas with the (poly)phenol-derived metabolite Pyr-s effec-
tively decreased the expression of Iba1 (Figure 6B). No differences were observed in the
expression of Iba1 in mice subretinally injected at 8 months (Figure 6C) or 9 mont s old
(Figure 6D).
Regarding the GFAP, an increase in its expression was observed in 4-month-old
non-diabetic mice upon intravitreal injection of Pyr-s (Figure 7A). Moreover, as previ-
ously described by our group [12], a decrease in the expression of GFAP was observed in
6 month-old mice wh n non-diabetic retinas were compared to diabetic retinas (Figure 7B).
Treatment of diabetic retinas with Pyr-s tends to increase the expression of GFAP (p = 0.2468)
at the same time-point (Figure 7B). No differences in the expression of GFAP were observed
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in older mice, subretinally injected, although there was a tendency of treatment with Pyr-s
decreasing the expression of GFAP (p = 0.2490), when non-diabetic retinas of 8-month-old
mice were compared to diabetic (Figure 7C).
In a previous study, we showed that the expression of Iba1 tends to increase in the
9-month-old diabetic retina but is not altered in older mice [12]. Here, we analyzed the
expression of Iba1 and GFAP in 8- and 9-month-old mice to understand if the administration
of Pyr-s before an advanced stage of DR (as previously established to be at 9 months) has a
positive effect on retinal homeostasis. Treatment of diabetic 9-month-old mice with a single
subretinal injection tends to decrease the expression of Iba1 in the neural retina (Figure 6D)
and has no effect in the 8-month-old mice (Figure 6C). Furthermore, the expression of
GFAP was not affected by Pyr-s in 8- (Figure 7C) or 9-month-old (Figure 7D) animals.
2.6. A Single Subretinal Injection of Pyrogallol-O-Sulfate Decreases the Expression of
Pro-Angiogenic VEGF in the RPE of a Diabetic Mouse Model
We have previously documented the dysregulation of the balance between pro- and
anti-angiogenic factors in the Ins2Akita mouse, with a significant increase in the expression
of VEGF with a concomitant decrease in the expression of PEDF in the neural retina of
9-month-old mice [12].
To further evaluate the effect of pyrogallol-O-sulfate in the expression profile of pro-
and anti-angiogenic factors with disease progression in the Ins2Akita mouse, we evaluated
the protein levels of PEDF (Figure 8) and VEGF (Figure 9) in neural retina and RPE cells of 4-
, 6-, 8-, and 9-month-old mice two weeks after intraocular injection of Pyr-s, as described in
Materials and Methods (Section 4.7.2). We were also interested in evaluating the expression
of glucose transporter, GLUT-1, as its expression was previously reported to be imbalanced
in diabetic retinas [15] (Figure 10).
The expression of anti-angiogenic PEDF was not altered in the neural retina of either
non-diabetic or diabetic mice, either by intraocular injection of vehicle or Pyr-s, at any of
the time-points evaluated (Figure 8A–D). Similarly, no differences were observed in the
RPE, independently of the genotype (Figure 8E–H).




Figure 8. Expression of PEDF in Ins2Akita mice after a single intravitreal or subretinal injection of pyrogallol-O-sulfate. 
Protein expression levels and representative Western blot images for the densitometric analysis in the retina (A–D) and 
RPE (E–H) of Ins2Akita (diabetic) mice and age-matched non-diabetic mice, 4- (A–E), 6- (B–F), 8- (C–G), and 9- (D–H) months 
old, injected intravitreally or subretinally with vehicle or Pyr-s. Protein levels were normalized to β-actin. Data are ex-
pressed as mean ± SD (n = 2 to 5 mice/group). Two-way ANOVA (genotype and treatment) with Sidak’s multiple compar-
ison test. 
The expression of pro-angiogenic VEGF was also evaluated. When analyzing the ef-
fect of a single intravitreal injection of Pyr-s in animals of 4 months of age, the expression 
of VEGF was not altered (Figure 9A); however, upon treatment with Pyr-s, the expression 
of VEGF tended to decrease (p = 0.1761) in the diabetic retina of 6-month-old mice (Figure 
9B), compared to vehicle. Unexpectedly, the expression of VEGF tended to increase (p = 
0.086) in non-diabetic retinas with 8-month-olds, upon treatment with Pyr-s (Figure 9C), 
but effectively decreased later in animals of 9 months (Figure 9D), with no alterations in 
the expression of this protein in older diabetic retinas. Regarding the RPE, treatment with 
Pyr-s did not impact the expression of VEGF in younger mice (Figure 9E,F), nor in older 
mice (Figure 9G,H), despite a tendency to decrease VEGF in diabetic mice (Figure 9G) 
which needs further confirmation. 
A tendency to increase the expression of VEGF was previously reported by our group 
in the RPE of diabetic Ins2Akita mice at 9 months of age [12]. Although Pyr-s treatment did 
not have an effect in the expression of VEGF in the RPE of diabetic animals of 9 months of 
age, it also did not increase its expression, revealing that it is not a promoter of the imbal-
ance in the expression of proteins involved in neovascularization.  
Figure 8. Cont.
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Figure 8. Expression of PEDF in Ins2Akita mice after a single intravitreal or subretinal injection of pyrogallol-O-sulfate. 
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RPE (E–H) of Ins2Akita (diabetic) mice and age-matched non-diabetic mice, 4- (A–E), 6- (B–F), 8- (C–G), and 9- (D–H) months 
old, injected intravitreally or subretinally with vehicle or Pyr-s. Protein levels were normalized to β-actin. Data are ex-
pressed as mean ± SD (n = 2 to 5 mice/group). Two-way ANOVA (genotype and treatment) with Sidak’s multiple compar-
ison test. 
The expression of pro-angiogenic VEGF was also evaluated. When analyzing the ef-
fect of a single intravitreal injection of Pyr-s in animals of 4 months of age, the expression 
of VEGF was not altered (Figure 9A); however, upon treatment with Pyr-s, the expression 
of VEGF tended to decrease (p = 0.1761) in the diabetic retina of 6-month-old mice (Figure 
9B), compared to vehicle. Unexpectedly, the expression of VEGF tended to increase (p = 
0.086) in non-diabetic retinas with 8-month-olds, upon treatment with Pyr-s (Figure 9C), 
but effectively decreased later in animals of 9 months (Figure 9D), with no alterations in 
the expression of this protein in older diabetic retinas. Regarding the RPE, treatment with 
Pyr-s did not impact the expression of VEGF in younger mice (Figure 9E,F), nor in older 
mice (Figure 9G,H), despite a tendency to decrease VEGF in diabetic mice (Figure 9G) 
which needs further confirmation. 
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in the RPE of diabetic Ins2Akita mice at 9 months of age [12]. Although Pyr-s treatment did 
not have an effect in the expression of VEGF in the RPE of diabetic animals of 9 months of 
age, it also did not increase its expression, revealing that it is not a promoter of the imbal-
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Figure 9. Expression of VEGF in Ins2Akita mice after a single intravitreal or subretinal injection of pyrogallol-O-sulfate. 
Protein expression levels and representative Western blot images for the densitometric analysis in the retina (A–D) and 
RPE (E–H) of Ins2Akita (diabetic) mice and age-matched non-diabetic mice, of 4 (A–E), 6 (B–F), 8 (C–G), and 9 (D–H) months 
old, injected via intravitreal or subretinal route with vehicle or Pyr-s. Protein levels were normalized to β-actin. Data are 
expressed as mean ± SD (n = 2 to 5 mice/group). * p < 0.05 by Two-way ANOVA (genotype and treatment) with Sidak’s 
multiple comparison test. 
Similarly to what was observed for PEDF and VEGF, the expression of GLUT-1 was 
not significantly altered by intraocular treatment with Pyr-s. In general, the expression of 
GLUT-1 in the neural retina of both non-diabetic and diabetic mice remained unchanged 
at all time-points, when compared to the injection vehicle (Figure 10D). Regarding the 
expression levels at RPE, a tendency to decrease (p = 0.1255) the expression of glucose 
transport in diabetic RPE of 4-month-old mice compared to non-diabetic mice (Figure 10E) 
was observed. We were unable to detect the expression of GLUT-1 in samples from 6-
month-old mice, which can most probably be attributed to the low levels in RPE protein 
isolates. No differences were detected in the RPE of older mice subretinally injected with 
Pyr-s (Figure 10F,G). 
Figure 9. Expression of VEGF in Ins2 kita ice after a single intravitreal or subretinal injection of pyrogallol-O-sulfate.
Protein expression levels and representative Western blot images for the densitometric analysis in the retina (A–D) and RPE
(E–H) of Ins2Akita (diabetic) mice and age-matched non-diabetic mice, of 4 (A–E), 6 (B–F), 8 (C–G), and 9 (D–H) months
old, injected via intravitreal or subretinal route with vehicle or Pyr-s. Protein levels were normalized to β-actin. Data are
expressed as mean ± SD (n = 2 to 5 mice/group). * p < 0.05 by Two-way ANOVA (genotype and treatment) with Sidak’s
multiple comparison test.
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The expression of pro-angiogenic VEGF was also evaluated. When analyzing the effect
of a single intravitreal injection of Pyr-s in animals of 4 months of age, the expression of
VEGF was not altered (Figure 9A); however, upon treatment with Pyr-s, the expression of
VEGF tended to decrease (p = 0.1761) in the diabetic retina of 6-month-old mice (Figure 9B),
compared to vehicle. Unexpectedly, the expression of VEGF tended to increase (p = 0.086)
in non-diabetic retinas with 8-month-olds, upon treatment with Pyr-s (Figure 9C), but
effectively decreased later in animals of 9 months (Figure 9D), with no alterations in the
expression of this protein in older diabetic retinas. Regarding the RPE, treatment with Pyr-s
did not impact the expression of VEGF in younger mice (Figure 9E,F), nor in older mice
(Figure 9G,H), despite a tendency to decrease VEGF in diabetic mice (Figure 9G) which
needs further confirmation.
A tendency to increase the expression of VEGF was previously reported by our group
in the RPE of diabetic Ins2Akita mice at 9 months of age [12]. Although Pyr-s treatment did
not have an effect in the expression of VEGF in the RPE of diabetic animals of 9 months
of age, it also did not increase its expression, revealing that it is not a promoter of the
imbalance in the expression of proteins involved in neovascularization.




Figure 10. Expression of GLUT-1 in Ins2Akita mice after a single intravitreal or subretinal injection of pyrogallol-O-sulfate. 
Protein expression levels and representative Western blot images for the densitometric analysis in the retina (A–D) and 
RPE (E–G) of Ins2Akita (diabetic) mice and age-matched non-diabetic mice, of 4 (A,E), 6 (B), 8 (C,F), and 9 (D,G) months 
old, injected via intravitreal or subretinal route with vehicle or Pyr-s. Protein levels were normalized to β-actin. Data are 
expressed as mean ± SD (n = 2 to 5 mice/group). Two-way ANOVA (age and genotype) with Sidak’s multiple comparison 
test. 
3. Discussion 
Classically regarded as a progressive microvascular complication of diabetes with an 
inflammatory background, DR remains one of the major causes of acquired visual impair-
ment and/or blindness among the diabetic population [13,23,24]. Although the exact 
mechanism underlying DR pathophysiology is not yet fully understood, it is believed that 
the chronic exposure to hyperglycemia triggers a cascade of biochemical and physiologi-
cal changes, causing inner BRB breakdown [25,26]. These events are potentiated by oxi-
dative stress and inflammation, which promote increase in the production of reactive ox-
idative species (ROS), cytokines, and growth factors, altogether contributing to visual im-
pairment or irreversible blindness [13]. 
As mentioned before, one of the major characteristics of DR is vascular changes along 
the progression of the disease, trigged by chronic and sustained hyperglycemia and hy-
poxia. Due to retinal ischemia during diabetes, the balance between pro- and anti-angio-
genic molecules is disrupted, leading to up-regulation of pro-angiogenic VEGF and down-
regulation of anti-angiogenic PEDF [27,28]. Our group has shown that sustained expres-
sion of PEDF up to 3 months by an episomal vector, both in cultures of human RPE cells 
and in the retina of a DR mice model after a single subretinal injection, decreased VEGF, 
GLUT1, and inflammation markers. As a consequence of the imbalance mostly between 
these two growth factors, neovascularization is promoted but the new blood vessels are 
usually weak, fragile, and leaky, which allows proteins, fluids, and debris to enter the 
Figure 10. Expression of GLUT-1 i I s2 kita mice after a single intravitreal or subretinal injection of pyrogallol-O-sulfate.
Protein expression levels and representative Western blot images for the densitometric analysis in the retina (A–D) and
RPE (E–G) of Ins2Akita (diabetic) mice and age-matched non-diabetic mice, of 4 (A,E), 6 (B), 8 (C,F), and 9 (D,G) months
old, injected via intravitreal or subretinal route with vehicle or Pyr-s. Protein levels were normalized to β-actin. Data
are expressed as mean ± SD (n = 2 to 5 mice/group). Two-way ANOVA (age and genotype) with Sidak’s multiple
comparison test.
Similarly to what was observed for PEDF and VEGF, the expression of GLUT-1 was
not significantly altered by intraocular treatment with Pyr-s. In general, the expression of
GLUT-1 in the neural retina of both non-diabetic and diabetic mice remained unchanged
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at all time-points, when compared to the injection vehicle (Figure 10D). Regarding the
expression levels at RPE, a tendency to decrease (p = 0.1255) the expression of glucose
transport in diabetic RPE of 4-month-old mice compared to non-diabetic mice (Figure 10E)
was observed. We were unable to detect the expression of GLUT-1 in samples from
6-month-old mice, which can most probably be attributed to the low levels in RPE protein
isolates. No differences were detected in the RPE of older mice subretinally injected with
Pyr-s (Figure 10F,G).
3. Discussion
Classically regarded as a progressive microvascular complication of diabetes with
an inflammatory background, DR remains one of the major causes of acquired visual
impairment and/or blindness among the diabetic population [13,23,24]. Although the exact
mechanism underlying DR pathophysiology is not yet fully understood, it is believed that
the chronic exposure to hyperglycemia triggers a cascade of biochemical and physiological
changes, causing inner BRB breakdown [25,26]. These events are potentiated by oxidative
stress and inflammation, which promote increase in the production of reactive oxidative
species (ROS), cytokines, and growth factors, altogether contributing to visual impairment
or irreversible blindness [13].
As mentioned before, one of the major characteristics of DR is vascular changes
along the progression of the disease, trigged by chronic and sustained hyperglycemia
and hypoxia. Due to retinal ischemia during diabetes, the balance between pro- and anti-
angiogenic molecules is disrupted, leading to up-regulation of pro-angiogenic VEGF and
down-regulation of anti-angiogenic PEDF [27,28]. Our group has shown that sustained
expression of PEDF up to 3 months by an episomal vector, both in cultures of human RPE
cells and in the retina of a DR mice model after a single subretinal injection, decreased
VEGF, GLUT1, and inflammation markers. As a consequence of the imbalance mostly
between these two growth factors, neovascularization is promoted but the new blood
vessels are usually weak, fragile, and leaky, which allows proteins, fluids, and debris to
enter the retina [13,14]. Moreover, we have shown that in a DR cell model, hyperglycemia
and hypoxia directly affect GLUT-1 expression and the secretory function of RPE cell [15].
It was found that not only the expression of GLUT-1 is increased when RPE cells are in
hypoxia under high glucose conditions, but also its membrane fraction increases under the
same conditions. The consumption of glucose is also affected, pointing to an increase in
the GLUT-1 expression to achieve an effective glucose transport [15].
At present, there are few effective treatments for DR. Tight glycemic control is the
most efficient therapy to slow the progression of DR [29,30]. Blood pressure should also
be closely monitored, since hypertension aggravates the disease by increasing blood flow
and causing mechanical damage to the vascular endothelial cells, thus stimulating the
production of VEGF [13,14]. However, current treatments for DR are designed to act on
later stages of this pathology, targeting ocular lesions resulting from the disease progression.
In pathologies associated with neovascularization, such as DR or wet AMD, intravitreal
administration of monoclonal antibodies or fusion proteins that block VEGF activity is
considered as first line therapeutic approach [31]. Considering the growing numbers of
diabetes incidence and prevalence [32,33] and that these forms of treatment only avoid the
progression of DR temporarily, there is a need to seek therapeutic alternatives that either
have longer lasting effects or can target DR in earlier stages of progression.
Knowing that targeting DR remains a challenge, it is important to understand how
we can prevent its progression; thus, our main goal is to investigate different and novel
therapeutic approaches towards DR, based on the biological proprieties of (poly)phenol-
derived metabolites.
There are several studies on the anti-diabetic effects of (poly)phenols showing these
compounds to influence the glycemia status through different mechanisms such as the
inhibition of glucose absorption in the gut or in peripheral tissues [8]. Some studies show
the inhibition of glucose transporters by (poly)phenols. For example, onion (poly)phenols
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have the capacity to protect diabetic patients from oxidative stress and (poly)phenols from
vegetables act as potent anti-diabetic agents by decreasing the levels of blood glucose and
increasing plasma insulin [34,35].
Studies specifically related to the effect of (poly)phenols or their metabolites on
retinal diseases are scarce. However, the interest in this topic increased in the last decade,
particularly in studies on the effect of resveratrol, as reviewed by Popescu et al. [36]. More
recently, the beneficial effect of different carotenoids and (poly)phenols in the prevention
and treatment of age-related ocular disorders was reviewed, highlighting the role of these
compounds in oxidative stress and inflammation [9]. In particular, in vitro and in vivo
studies have revealed that a variety of nutraceuticals have significant antioxidant and anti-
inflammatory properties that may inhibit the early diabetes-driven molecular mechanisms
that induce DR, reducing both the neural and vascular damage typical of DR [37,38].
The presence of sulfated metabolites of pyrogallol was confirmed for the first time by
Santos and colleagues in human plasma from volunteers after ingestion of a fruit purée [6].
The metabolite Pyr-s was found in in some volunteers, in concentrations up to 20 µM.
Pyr-s metabolites have been recently studied in different models of neurodegenerative and
cardiovascular disorders, showing the ability of these small molecules to cross the blood-
brain barrier, modulate the brain cell towards neuroprotection, and affect cardiomyocyte
beating following prolonged stimulation [3,5]. Furthermore, it was shown for the first time
that Pyr-s was also effective in preventing oxidative damage in brain endothelial cells and
attenuating inflammation in microglial cells [3].
Here we aim to address the effect of Pyr-s in the expression of proteins involved in
inflammation and neovascularization, using RPE cells and a diabetic mouse model. To the
best of our knowledge, this is the first time this (poly)phenol-derived metabolites have
been tested in RPE cells, so as a first approach, it was important to evaluate how RPE cells
are affected by the presence of Pyr-s. RPE cells, under high glucose and hypoxia, were not
metabolically affected by treatment with Pyr-s (6.5 µM, 24 h).
The levels of PEDF and VEGF, whose expression is imbalanced in DR patients, as well
as the glucose transporter GLUT-1 were analyzed in RPE cells treated with a single dose of
Pyr-s in three different protocols. When Pyr-s was added before the induction of hypoxia,
the expression of anti-angiogenic PEDF tended to decrease at certain timepoints. On the
other hand, no alterations in the expression of the proteins evaluated were observed when
Pyr-s was added after the establishment of hypoxia. However, the expression of VEGF was
effectively decreased when RPE cells were exposed to Pyr-s for 24 h, starting before the
induction of hypoxia.
This compound was described as being further metabolized by brain endothelial
cells [3]. Considering this, the same characterization in RPE cells upon exposure to Pyr-s
could help understand whether these metabolites are further metabolized by the cell, to
further study their physiological relevance, and possibly explain the differences in the
expression of the proteins analyzed according to the time of exposure to Pyr-s. Moreover,
neither PEDF nor VEGF secreted levels were analyzed in this study. Secreted proteins’
levels should be measured in the cell culture medium to better understand if treatment
with Pyr-s has an impact in the secretory function of RPE cells.
Several studies correlate the bioactivity of (poly)phenol-derived metabolites with an
improvement in vascular function in healthy humans, linked to the presence of newly
identified plasma metabolites [39,40]. In addition, a study showed that epigalloccatechin-3-
gallate, the main plant-derived (poly)phenol of green tea, effectively protected RPE cells
from cell death and attenuated mRNA expressions of key angiogenic factors (MMP-9, VEGF,
VEGFR2) by inhibiting the generation of ROS, with further evidence on the inhibition of
ocular neovascularization and vascular permeability [9]. In the same line, resveratrol, also
a plant-derived (poly)phenol, present in red wine, as well as other dietary (poly)phenols,
were shown to have anti-angiogenic properties, as reviewed in [41]. Our results point
to a potential anti-angiogenic effect of Pyr-s on RPE cells that is dependent on the time
of exposure of the cells to the bioactive metabolite. In addition, further studies focused
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on the vascular features performed in a more robust hyperglycemia retinal model would
help to understand the extension of the potential of treatment with Pyr-s in DR prevention
and progression.
Regarding the levels of GLUT-1, which were not affected by Pyr-s in any of the
experimental setups, an evaluation of the glucose consumption by the cells may be useful
to determine if Pyr-s affects glucose uptake without significantly changing the expression
of GLUT-1 in the cell membrane.
Further studies may be conducted to assess the effect of Pyr-s in RPE cells, either with a
role in angiogenesis or ocular inflammation. Assessing the secreted levels of other cytokines
such as TNF-α or IL-1β would allow a full characterization of the secretory profile of RPE
cell upon treatment with Pyr-s and, therefore, the biological outcome towards inflammation.
Moreover, the distinct outcomes in RPE cells upon treatment with Pyr-s highlights the
importance of different experimental approaches in studying multifactorial diseases such
as DR.
To further study the therapeutic potential of Pyr-s, we evaluated, after intraocular
injection of the metabolite in Ins2Akita mice, the expression of several proteins known to
be involved either in the DR characteristic inflammatory process or in neovascularization.
Diabetic and age-matched non-diabetic animals were grouped by ages covering different
stages of DR progression, and the eye injected with vehicle or Pyr-s at the same concentra-
tion as used in vitro. A single injection was performed, intravitreally or subretinally, and
the expression of several proteins of interest was measured in the neural retina and RPE.
We have previously characterized the expression of several markers of DR progression in a
spontaneous Type 1 Diabetes Mellitus model, the Ins2Akita, and found an increase in the
expression of microglia marker Iba1 in the neural retina of 6-month-old diabetic mice [19].
At the same time point, the expression of GFAP decreases in diabetic retina, compared to
the non-diabetic retina [19].
The expression of the microglia marker, Iba1, significantly decreased in diabetic
retina after a single intravitreous injection of Pyr-s in 6-month-old animals. In accordance
with our results, digested raspberry metabolites used at physiological levels previously
exhibited anti-inflammatory activity, not only by the reduction of Iba1 expression, but also
by inhibiting the release of nitric oxide and TNF-α [42]. Consistent with the activation of
microglia described in both early DR patients and other animal models, our results in the
Ins2Akita mouse showed an increased expression of Iba1 [21,23]. This seems to be thwarted
by treatment with pyrogallol-O-sulfate in animals with early (6-month-old) DR features,
highlighting the potential of Pyr-s to prevent microglial activation in the diabetic retina.
In the normal retina, astrocytes label more heavily with anti-GFAP than the Müller
cell endfeet (which predominately express the type-III intermediate filament vimentin),
but after injury, there is a rapid up-regulation of GFAP by Müller cells [43,44]. In our
studies, elevated GFAP expression was observed early upon intravitreal injection of Pyr-s
in 4-month-old non-diabetic mice and reached values close to the control in later stages
of the disease. A tendency to increase the expression of GFAP in 6-month-old diabetic
retinas upon intravitreal injection of Pyr-s was observed. As it is described that macroglia
undergoes prominent changes in early DR, which includes a decrease in the astrocytic pop-
ulation and reduced coverage of retinal blood vessels by glial cell processes [43,45], and to
date no study has been able to connect increased levels of GFAP to any functional outcome,
these results need further confirmation regarding the astrocytic population to evaluate
whether Pyr-s has a role in maintaining the number of astrocytes, protecting the retinal
blood vessels, or if this tendency to increase the expression of GFAP enhances macroglia
activation promoting the progression of DR. Furthermore, an increased permeability of
BRB in the early stages of DR in Ins2Akita mice [21,22] has been described, in line with the
decreased levels of the astrocyte marker GFAP previously observed in all tested ages [12].
Because the injection of the vehicle does not increase the expression of GFAP, when the
diabetic retina is compared to non-diabetic (Supplementary data), our hypothesis relies on
a non-pathological role of Pyr-s driven by GFAP expression.
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Concerning the levels of proteins contributing to neovascularization, there is no
statistical significance in the results regarding the expression of anti-angiogenic PEDF, but
there was a tendency to decrease the expression of pro-angiogenic VEGF in the diabetic
retina of the 6-month-old animals upon injection with Pyr-s. In agreement with what
is described for patients with proliferative DR, we previously observed an increase of
VEGF in late stages of the disease in Ins2Akita mice both in the neural retina and the
RPE [12,22]. However, at earlier stages, we observed significantly decreased levels of
VEGF in RPE cells and a slight decrease in the neural retina [12]. Here, a single intraocular
injection of Pyr-s at the physiological concentration found in human plasma tended to
decrease the expression of VEGF at earlier stages. These studies, despite requiring further
addressing, together with those reviewed by Cao et al. [41], raise significant interest in
(poly)phenols as an important group of therapeutic natural compounds in the treatment of
neovascular-dependent disorders.
The expression of glucose transporter, GLUT-1, also tended to decrease in the RPE of
4-month-old mice treated with Pyr-s by intravitreal injection, showing that it is possible
to have an effect promoted by Pyr-s in the outer layer of the retina after intravitreal
administration. Additionally, the expression of GLUT-1 decreases in non-diabetic RPE
from 8-month-old mice upon a single subretinal injection of Pyr-s.
Overall, our results point to a role of pyrogallol-O-sulfate in different stages of diabetic
retinopathy progression by affecting the expression of pro-angiogenic VEGF in in vitro
RPE cells and preventing microglia activation earlier after a single intraocular injection in
diabetic mice models.
4. Materials and Methods
4.1. Cell Culture
D407 cells, a human spontaneously transformed RPE cell line [46], were kindly pro-
vided by Dr. Jean Bennett (University of Pennsylvania, Philadelphia, PA, USA). Cells
were maintained in 5% CO2–95% air at 37 ◦C and grown in Dulbecco’s Modified Ea-
gle Medium (DMEM) with 5.5 mM D-glucose (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA),
1% glutamine (Sigma-Aldrich, St. Louis, MO, USA), and 5% fetal bovine serum (FBS,
Sigma-Aldrich, St. Louis, MO, USA). For sub-culturing, cells were dissociated with a
trypsin-Ethylenediaminetetraacetic Acid (EDTA) solution (Sigma-Aldrich, St. Louis, MO,
USA), split 1:5 and cultured in 21 cm2 culture flasks (Orange Scientific, Braine-lÁlleud,
Belgium). Culture medium was changed every 2 days.
4.2. Glucose and Hypoxia
For the experiments regarding the effect of glucose, RPE were seeded at a density of
3 × 105 cells/well in a 6-well plate (Orange Scientific, Braine-lÁlleud, Belgium). For each in-
dependent experiment, cells were exposed to either DMEM with 5.5 mM glucose, to mimic
a physiological concentration, DMEM with 25 mM glucose, to mimic a hyperglycemic
condition, or DMEM with 5.5 mM of D-glucose containing D-Mannitol (AppliChem GmbH,
Darmstadt, Germany) with a final concentration of 25 mM, as an osmolarity control, as it is
known to be metabolically inert in mammalian cells as energy source [47].
Desferrioxamine (DFO, Sigma-Aldrich, St. Louis, MO, USA), an iron chelating agent,
was used as a hypoxia-mimetic agent at a final concentration of 100 µM [48,49]. Under nor-
moxic conditions and in the presence of iron, hypoxia-inducible factor-1α is hydroxylated
and subsequently degraded by the proteasome. In the presence of DFO, the iron required
for the enzymatic activity of prolyl hydroxylases is removed by its chelating capacity,
allowing hypoxia-inducible factor-1α to be stabilized and dimerize with its β-subunit,
originating a functional complex that is translocated to the nucleus [48].
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4.3. Treatment with (Poly)Phenol-Derived Metabolites
Pyrogallol-O-sulfate was chemically synthesized as described by Pimpão et al [6].
To evaluate the effect of the polyphenol metabolite, RPE cells were plated with DMEM
with 5.5 mM glucose to mimic a physiological concentration. The next day, the medium
was changed to DMEM with 5.5 mM glucose or DMEM with 25 mM glucose to mimic a
hyperglycemic condition. Depending on the therapeutic approach to test, pyrogallol-O-
sulfate (Pyr-s, 6.5 µM) was incubated in media without FBS in three different protocols
represented below (Figure 11).
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hypoxia. The metabolite was removed from the cell culture after the incubation period. (B) A single dose after induction 
of hypoxia. Cells were exposed to the metabolite for 8 h. (C) A single dose, 24 h after the increase of the glucose in the 
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pression of PEDF, VEGF, and GLUT-1 was analyzed in whole cells lysates by Western blot. 
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0.125 mg/mL; and 0.0625 mg/mL) prepared in miliQ water. Samples were also diluted in 
miliQ water in 1:5 or 1:10 ratios for cell lysates and retinas, respectively. The cell and 
standard samples were loaded into a 96-well plate, and the dye reagent added to each 
well. The absorbance was read in a Biotrak II Plate reader (Amersham Biosciences, Amer-
sham, UK) at 595 nm and concentration of protein was determined by linear regression. 
4.5. MTT Assay 
D407 cells were seeded at a density of 2 × 104 cell/well in a 48-well plate, with a vol-
ume of DMEM of 500 µL/well with 5.5 mM glucose (supplemented with 1% penicil-
lin/streptomycin and 5% FBS), hence considered the physiological condition. After 24 h, 
the medium was changed, and cells were exposed to different conditions as previously 
described in 2.1.3. Treatment with the polyphenolic metabolite pyrogallol-O-sulfate was 
performed according to the protocol described in Figure 11C. 
In each well, 25 µL of MTT (Sigma-Aldrich, St. Louis, MO, USA) at a final concentra-
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4.4. Protein Extraction and Quantification
4.4.1. Whole Cell Lysates
To obtain cellular lysates, cells were washed with cold PBS 1X and homogenized
in radioimmunoprecipitation assay buffer (RIPA) (50 mM Tris-Hydrochloric acid (HCl,
Sigma-Aldrich, St. Louis, MO, USA) pH 7.4, 1% NP-40 (Millipore, Burlington, MA, USA),
0.25% Na-deoxycholate (Sigma-Aldrich, St. Louis, MO, USA), 150 mM Sodium chloride
(Sigma-Aldrich, St. Louis, MO, USA) and 1 mM EDTA (Sigma-Aldrich, St. Louis, MO,
USA) su plemented with protease inhibitors cocktail 1× (Roche, Basel, Switzerland).
The cells w re then scrapped from he b ttom of the well, kept n ice for 20 m n, cen-
trifuged (16.100× g, 20 min, 4 ◦C) and the supernatant collected and stored at −20 ◦C until
further analysis.
4.4.2. Protein Quantification
Protein concentration as deter ined by the Bradford Method [50], using the Bio-Rad
protein assay dye reagent concentrate (BioRad, Hercules, CA, USA) in cellular lysates
and retinal tissue. Bovine serum albumin (NZYTech, Lisboa, Portugal or Thermo Fisher
Scientific, Waltham, MA, USA) was used as standard (1 mg/mL; 0.5 mg/mL; 0.25 mg/mL;
0.125 mg/mL; and 0.0625 mg/mL) prepared in miliQ water. Samples were also diluted
in miliQ water in 1:5 or 1:10 ratios for cell lysates and retinas, respectively. The cell and
standard samples were loaded into a 96-well plate, and the dye reagent added to each well.
The absorbance was read in a Biotrak II Plate reader (Amersham Biosciences, Amersham,
UK) at 595 nm and concentration of protein was determined by linear regression.
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4.5. MTT Assay
D407 cells were seeded at a density of 2 × 104 cell/well in a 48-well plate, with a
volume of DMEM of 500 µL/well with 5.5 mM glucose (supplemented with 1% peni-
cillin/streptomycin and 5% FBS), hence considered the physiological condition. After 24 h,
the medium was changed, and cells were exposed to different conditions as previously
described in Section 4.2. Treatment with the polyphenolic metabolite pyrogallol-O-sulfate
was performed according to the protocol described in Figure 11C.
In each well, 25 µL of MTT (Sigma-Aldrich, St. Louis, MO, USA) at a final concentra-
tion of 0.25 mg/mL was incubated at 37 ◦C for 3 h. At the end of the incubation period, the
formazan was dissolved with 250 µL of 0.04 N HCl in isopropanol 100% and the absorbance
was measured in a Biotrak II Plate reader (Amersham Biosciences, Amersham, UK) at
540/620 nm.
4.6. Immunoblotting
The samples were diluted in RIPA buffer with 4 × Laemmli Sample Buffer (BioRad,
Hercules, CA, USA) and heated at 95 ◦C for 5 min for deoxyribonucleic acid (DNA)
denaturation. A total of 30 µg of protein was loaded in a 10 to 15% SDS acrylamide gel,
as suitable, along with 3 µL of a PageRuler Plus Pre-stained Protein Ladder 2× (Thermo
Fisher Scientific, Waltham, MA, USA). Electrophoresis was performed at 100–120 V in
electrophoresis buffer (25 mM Tris-HCl, 192 mM Glycine (Enzymatic, Loures, Portugal)
and 0.1% SDS (AppliChem GmbH, Darmstadt, Germany) until the dye reached the bottom
of the gel.
Proteins were electrotransferred to polyvinylidene difluoride (GE Healthcare Life
Sciences, Chicago, IL, USA) previously activated for 20 s with methanol, followed by
deionized H2O for 20 s and cold transfer buffer (0.192 M glycine, 0.025 M Tris pH 8.3,
10% methanol) for 5 min, or nitrocellulose (NC, (GE Healthcare Life Sciences, Chicago,
IL, USA)) membrane through a semi-dry transfer method for 20 min and 20 V (Trans-Blot
Turbo®, BioRad, Hercules, CA, USA). The membranes were then blocked with 5% bovine
serum albumin in Tris buffered saline (TBS) with 0.1% Tween-20 (Sigma-Aldrich, St. Louis,
MO, USA) (TBS-T) for 1 h at room temperature, with gently agitation. Primary antibodies,
listed in Table 1, diluted in 5% bovine albumin serum in TBS-T were incubated overnight
at 4 ◦C with gentle agitation. The membranes were subsequently washed with TBS-T
and incubated with the correspondent secondary antibodies IgG conjugated with HRP
(Santa Cruz Biotechnology, Dallas, TX, USA) for 1 h at room temperature. After washing
three times for 5 min each with TBS-T, the enhanced chemiluminescence Select Western
Blotting Detection Reagent (1:1, GE Healthcare Life Sciences, Chicago, IL, USA) was used
for visualization in a ChemiDocTM imaging System (BioRad, Hercules, CA, USA). To ensure
that samples were evenly loaded, the membranes were stripped and re-probed for β-actin.
For stripping, the membrane was washed three times with TBS-T for 5 min, incubated
for 5 min with 0.2 N sodium hydroxide (NaOH, Sigma-Aldrich, St. Louis, MO, USA) or
mild stripping solution (glycine, SDS, Tween-20 pH = 2.2), followed by a triple TBS-T wash
for 5 min and incubated with the new primary antibody.
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Table 1. List of primary and secondary antibodies, with the respective technical information, used
for detection of proteins of interest by Western blot.
Primary Antibody Dilution Reference Brand
VEGF-A 1:500–1:1000 ab46154 Abcam, Cambridge, UK
PEDF 1:500–1:1000 07-280 Merck Millipore, Burlington,MA, USA
Iba1 1:500 SAB2500041 Sigma-Aldrich, St. Louis,MO, USA
GFAP 1:10,000 ab7260 Abcam, Cambridge, UK
GLUT-1 1:2000 ab32551 Abcam, Cambridge, UK
β-actin 1:5000 A5441 Sigma-Aldrich, St. Louis,MO, USA
Goat anti-mouse igG-HRP 1:5000 sc-516162 Santa Cruz Biotechnology,Dallas, TX, USA
Goat anti-rabbit igG-HRP 1:5000 sc-2004 Santa Cruz Biotechnology,Dallas, TX, USA
Donkey anti-goat igG-HRP 1:5000 sc-2020 Santa Cruz Biotechnology,Dallas, TX, USA
4.7. Animals
Male C57BL/-Ins2Akita-6J heterozygote and C57BL/6J age-matched (wild-type) mice
from The Jackson Laboratory (Bar Harbor, ME, USA) were used. These mice present a dom-
inant point mutation in the insulin 2 gene that spontaneously induces diabetes, developing
hyperglycemia as early as 4 weeks of age [21]. With the progression of hyperglycemia,
diabetic mice can develop retinal complications similar to what is observed in DR [21],
making them a good model to study early alterations of DR.
4.7.1. Housing
Animals were maintained and handled in accordance with the Portuguese and Eu-
ropean Laboratory Animal Science Association (FELASA) Guide for the Care and Use of
Laboratory Animals, the European Union Council Directive 2010/63/EU for the use of
animals in research and the Association for Research in Vision and Ophthalmology (ARVO)
for the use of animals in ophthalmic and vision research. Animal experiments have been
performed under the approval of the Portuguese national body (DGAV—Direção Geral de
Alimentação e Veterinária) and the institutional body.
Mice were housed in individually ventilated cages, under controlled temperature,
with continuous access to food and water, and on a 12 h dark/light cycle. To confirm the
diabetic phenotype, blood glucose levels were measured 2 months after birth, with a drop
of blood obtained by a tail cut on a reactive glucose strip (Contour Next, Ascensia Diabetes
Care, Basel, Switzerland). The mice presenting blood glucose levels equal or higher than
250 mg/dL were considered diabetic [21].
Male diabetic C57BL/-Ins2Akita-6J and non-diabetic C57BL/-Ins2Akita-6J age-match
mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used as DR model. The main
goal of the following experimental design was to assess the effect of Pyr-s on the expression
of proteins involved in inflammation and neovascularization in the neural retina and RPE
of animals at different ages (4, 6, 8, and 9 months of age). These time-points were set taking
into consideration previous work where molecular and cellular alterations were observed
consistent with clinical observations of DR progression [21]. Moreover, we have previously
found alterations in protein levels important for DR pathophysiology in both neural retina
and RPE of the Ins2Akita mice up to 12 month old [12]. As such, the following experiments
were designed for a role of Pyr-s in both the early stages of DR but also in later stages of
the disease. The estimated number of subjects in each group, for a statistically significant
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difference (p < 0.05), with a difference in means of 50%, was at least 5 animals per group.
For this study, a total of 70 animals were used.
4.7.2. Intraocular Injections of Pyrogallol-O-Sulfate in C57BL/Ins2Akita Mice
The animals were randomly assigned for different experimental groups: C57Bl/6
(non-diabetic) sham; C57Bl/6 (non-diabetic) Pyr-s injection; C57BL/-Ins2Akita-6J (diabetic)
sham; and C57BL/-Ins2Akita-6J (diabetic) Pyr-s injection. The experimental protocol for the
intraocular injections is schematized below (Figure 12).
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Figure 12. Schematic representation of the intraocular injections of pyrogallol-O-sulfate in diabetic and non-diabetic mice,
targeting different retinal cells at different stages of DR progression. The expression of proteins having a role in inflammation
and neovascularization were assessed by Western blot, two weeks after a single injection, either intravitreous or subretinal.
Intraocular injections were performed in anesthetized animals with Avertin® ((2,2,2-
tribromoethyl alcohol (Sigma-Aldrich, St. Louis, MO, USA) with 2-methyl-2-butanol
(Sigma-Aldrich, St. Louis, MO, USA); intraperitoneal injection of 0.5 mL/25 g) and
pupils were dilated using 1% tropicamide (Edol, Linda-a-Velha, Portugal). Cornea was
superficially anesthetized with Anestocil (Edol, Linda-a-Velha, Portugal) as an eye drop.
A 30-gauge needle was used to puncture a hole approximately 1 mm below the limbus in
the immobilized animals. The left eye was injected intravitreally or subretinally with 2 µL
of Pyr-s at a final concentration of 6.5 µM or saline solution in one eye using a Hamilton
syringe 10 µL 701 RN injector at 50 nL/s. The non-injected contralateral eye was used as
control. After the injection, gentamicin and dexamethasone were applied in the injected
eye to reduce the risk of infection.
No changes in grooming, behavior, food, or water consumption were observed after
injection. Additionally, visual inspection of the eyes of animals within the experimental
groups revealed no signs of ocular inflammation nor changes in overall health status.
4.7.3. Retina and RPE Protein Extraction
Two weeks after Pyr-s injection, the animals were humanely sacrificed by cervical
dislocation and the eyes removed. The neural retina and RPE were isolated, as previously
described [51]. Samples were mechanically homogenized in ice-cold RIPA buffer containing
a protease inhibitor cocktail and kept on ice for 20 min. The extracts were then centrifuged
(20 min, 4 ◦C, 16.100× g). The supernatant was collected, and protein quantified by Braford
method, as previously described, with a dilution of 1:10, for Western blot. The samples
were stored at −80 ◦C until use.
4.8. Statistical Analysis
Arithmetic means are given with standard error of the mean (SEM) or standard devia-
tion (SD), when more suitable. Statistical analysis was performed using an unpaired t-test
with or without Welch’s correction, one-way analysis of variance (ANOVA) with Dunnet’s
Int. J. Mol. Sci. 2021, 22, 11402 20 of 22
multiple comparison test, or two-way ANOVA followed by the Sidak’s or Bonferroni’s
multiple comparison test for multiple comparisons. A value of p < 0.05 was considered to
be statistically significant, and a trend change in expression was considered when p-value
was below 0.25, as previously published [12].
5. Conclusions
In short, our data demonstrate that exposure of RPE cells to the (poly)phenol-derived
metabolite pyrogallol-O-sulfate effectively decrease the expression of VEGF in cells un-
der high glucose and hypoxia in certain experimental conditions. Additionally, a single
intraocular injection of pyrogallol-O-sulfate was able to decrease the expression of the
microglial marker Iba1 in the diabetic retina earlier in the disease course. Hence, our
findings open an opportunity to further explore this metabolite as a therapeutic approach
towards inflammation in DR.
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